Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 20 of 20 results for interferon beta

  1. Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)?

    effective when extended into secondary progressive MS (for example, beta interferon). Direct neuroprotection strategies...

    Research recommendation
    Published
    9 June 2015

  2. icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)

    NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .

    Medtech innovation briefing
    Published
    29 March 2022

  3. Ofatumumab for treating relapsing multiple sclerosis (TA699)

    Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.

    Technology appraisal guidance
    Published
    19 May 2021
    View recommendations

    Sections for TA699

  4. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis (TA32)

    This guidance has been updated and replaced by NICE technology appraisal guidance 527.

    Technology appraisal guidance
    Published
    23 January 2002

  5. Cladribine for treating relapsing–remitting multiple sclerosis (TA616)

    Evidence-based recommendations on cladribine (Mavenclad) for relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Last updated
    21 May 2024
    View recommendations

    Sections for TA616